5. REFERENCES
Zwaan CM, Reinhardt D, Hitzler et al., Acute leukemias in children with Down Syndrome. Hematol Oncol Clin North Am. 2010; 24(1): 19-34.
Hashle H, Abrahamsson J, Arola M, et al.; Myeloid leukemia in Children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia. 2008; 22(7): 1428-30.
Creutzig U, Reinhardt D, Diekamp S, et al., AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005; 19(8): 1355-60.
Taga T, Tomizawa D, Takahashi H and Adachi S. Acute Myeloid Leukemia in Children: Current status and future Directions. Pediatrics International. 2016; 58, 71-80.
Lam GKS, Leung AWK, Ha SY et al., Acute Leukemia in Down Syndrome Children in Hong Kong A Retrospective Review. J Pediatr Hematol Oncol 2016;38:102-6.
Lins MM, Mello MJG, Riberior RC, Camargo B, Fatima A, and Thuler L. Survival and Risk factors for Mortality in Pediatric Patients with Acute Myeloid Leukemia in a Single Reference Center in Low-Middle-Income Country. Annals of Hematology. 2019; 98(6):1403-11.
Ravindranath Y, Abella E, Krischer JP, et al., Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8489. Blood. 1992;80(9): 2210-14.
Stewart CF. Treating children with acute lymphoblastic leukemia and Down syndrome: pharmacokinetics provides insight into vincristine therapy. Pediatr Blood Cancer. 2009; 52(1):1-2.
Yamashita Y, Tohda S, nagata K, Suzuki T, Imai Y, and Nara N. The In Vitro Effect of Vincristine on the Blast Cell Renewal in Acute Myeloblastic Leukemia. Jpn J Med. 1991; 30(5): 412-9.
Zwaan CM, Kaspers GJL, Veerman AJP et al., Different drug sensitivity profile of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99:245-251.
Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema NA, Bhatia S. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2005; 106(13): 4043-9.
Matloub et al. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group. Blood Adv. 2019; 3(11): 1647-5.
Al-Ahmari A, Shah N, Sung L, et al., Long-term results of an Ultra Low-Dose Cytarabine based regimen for the treatment of Acute megakaryoblasti Leukaemia in Children with Down Syndrome. Br J Haematol. 2006;133(6):646-648.
Taub JW, Berman JN, Hitzler JK, Sorrell AD et al., Improved Outcomes for Myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial. Blood. 2017; 129: 3304-3313.
Uffman M, Rasche M, Zimmerman M et al., Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood. 2017;129(25):3314-3321.